Page 74 - Merck Sharp News Today

BERLIN--(BUSINESS WIRE)--Regulatory News:NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that top-line data from the ongoing NOX-A12 Phase 1/2 GLORIA trial in brain cancer will be...

In this article, we discuss the 10 most profitable biotech companies in the world.

Albany NY, United States: Stroke is a restorative condition that happens when there is interference in the blood supply to the brain because of blockage of veins, which can prompt the death of cerebrum cells or a person.

A large study from Brazil has now confirmed that the drug ivermectin does not help against Covid-19. Rodrigo Urzagasti/dpaA new study from Brazil has confirmed that ivermectin - the drug hoarded from pharmacies after vaccination sceptics made unfounded claims of its effects - does nothing to help ag...

First-line pembrolizumab plus nab-paclitaxel may improve some outcomes over chemotherapy alone in advanced triple-negative breast cancer.

A new study from Brazil has confirmed that ivermectin - the drug hoarded from pharmacies after vaccination sceptics made unfounded claims of its effects -

This randomized clinical trial examines the effect of early administration of the PCSK9 inhibitor alirocumab on coronary atherosclerosis using serial multimodal

A new tablet available in Australia, Molnupiravir (Lagevrio), has proved in human trials that it can eliminate actively infectious Covid-19 by day three of treatment.

1 April 2022, Merck Sharp & Dohme New Zealand Limited (MSD) says that KEYTRUDA has 20 indications and is now available for use in combination with lenvatinib*, to treat eligible women with a type of advanced uterine cancer called endometrial carcinoma

Investegate announcements from NetScientific PLC, PDS Provides Business Update & Full-Year Results